The failure to build a PCR for proteins wasnt biologys fault, argues Proteins.1. The Finnish startup claims its enzyme-free chip achieves 1,000x sensitivity over current tests, putting it in Quanterix territory. Independent validation pending.
Proteins.1, a Finnish startup emerging from VTT with €4.7M in pre-seed funding, claims its enzyme-free magnetic cycling technology on solid-state chips achieves single-molecule protein detection at 1,000x the sensitivity of current gold-standard platforms. The company argues that decades of failed attempts to build a PCR equivalent for proteins failed due to instrument limitations, not inherent biological complexity. Unlike Quanterix's Simoa platform, which uses enzyme-based digital immunoassay to reach attomolar sensitivity, Proteins.1 moves and reads individual molecules directly via magnetic fields, eliminating amplification chemistry and the cold-chain logistics it requires.
For decades, biotech researchers tried to build a PCR equivalent for proteins — a machine sensitive enough to detect single protein molecules the way PCR detects individual DNA strands. Every attempt failed. The standard explanation was that proteins were simply harder to work with than DNA. The CEO of Proteins.1, a Finnish startup that launched this week, has a different answer: the biology was never the problem. The instruments were.
Proteins.1 emerged from VTT, Finland's state research institute, with €4.7 million in pre-seed funding led by Lifeline Ventures and Cloudberry Ventures, plus grant support from Business Finland, according to VTT's launch announcement. The core technology was discovered at VTT in 2018 and independently replicated through VerSiLib, a four-year EIC Pathfinder project that received €3 million in EU funding (grant agreement 101046217). The company was founded in 2025 and is based in Espoo, Finland. Proteins.1 claims its enzyme-free approach uses physics-based magnetic cycling on a solid-state chip to detect proteins at sensitivity levels up to 1,000 times better than current gold-standard platforms — at single-molecule scale.
That claim puts Proteins.1 in the same performance class as Quanterix, a Massachusetts-based diagnostics company whose Simoa platform demonstrated more than 1,200-fold sensitivity improvement over conventional ELISA using enzyme-based digital immunoassay, according to peer-reviewed literature. Simoa reaches the attomolar range — able to count individual protein molecules per liter of fluid. Quanterix commercialized Simoa starting in 2016 and it has become standard for biomarker research in pharmaceutical drug development. Proteins.1 is making a similar sensitivity claim via a fundamentally different route: replacing enzymatic signal amplification with magnetic cycling.
"We don't need enzymes to do what enzymes do," said Prateek Singh, Proteins.1's chief executive, in the company's launch announcement. "We use magnetic fields to move single molecules and read them directly off a chip surface. No amplification chemistry required."
The distinction matters because enzyme-based systems are temperamental. Simoa-style immunoassays require precise temperature control, careful reagent preparation, and consistent lot-to-lot performance to maintain antibody activity. A solid-state chip with magnetic cycling sidesteps those constraints. Proteins.1 argues its architecture is both simpler and more robust in field conditions — and that eliminating enzymes removes the cold-chain logistics that currently limit where high-sensitivity protein tests can be run.
The global diagnostics market exceeds €100 billion annually, and the case for early detection is well-established: catching disease earlier consistently improves outcomes and reduces treatment costs. Current high-sensitivity protein detection requires specialized instruments in centralized labs. If enzyme-free single-molecule detection can be engineered for multiplexed protein panels — measuring dozens or hundreds of proteins simultaneously — it could bring high-sensitivity detection to settings that cannot support a traditional lab infrastructure.
That is a significant "if." The 1,000-fold sensitivity figure is company-asserted based on VTT internal validation and EU-funded replication. No independent peer-reviewed clinical study confirming the result has been published. Proteins.1 plans to publish its first external validation data later in 2026. US and Finnish patents have been granted, with international applications pending.
The pre-seed round of €4.7 million is modest relative to the capital requirements of regulated clinical diagnostics. Moving from research-use-only instruments to FDA clearance or CE marking — necessary before results can inform patient care — typically requires years of additional validation and substantially more capital. Diagnostics investors have learned to treat sensitivity claims from pre-commercial companies with caution. Quanterix has accumulated years of real-world performance data and has invested heavily in multiplexed panels. The gap between RUO instrumentation and regulated clinical use is a road that has ended many diagnostics ambitions.
Proteins.1 is not a drug story. It is a hardware instrumentation bet — and those have their own track record of underdelivering relative to early promises. The CEO's framing of a decades-long instrumentation failure is compelling, and VTT's track record of translating sensing research into commercial spinouts adds credibility. The peer-reviewed data is absent. The pre-seed is small. The path to clinical use is long.
The first external validation data, expected later this year, will be the real test. If independent confirmation supports the sensitivity claim, the instrumentation argument becomes a story worth revisiting at length.
Story entered the newsroom
Assigned to reporter
Research completed — 5 sources registered. (1) Proteins.1 VTT spinout, tech invented 2018, not a fresh startup. (2) 1000x sensitivity claim is same order as Quanterix Simoa (>1200-fold) — diffe
Draft (674 words)
Reporter revised draft (680 words)
Reporter revised draft based on fact-check feedback
Published (680 words)
@Curie — story_10090, intake score 68/100, beat biotech. Pipeline at capacity (5/5 active) — held in assigned until a slot opens. Finnish deeptech, 4.7M euro pre-seed, VTT transfer. Enzyme-free single-molecule protein amplification on a solid-state chip, 1000x sensitivity claim versus gold standard. Calls it a platform play, not incremental. Flag for @Rachel: biotech type0 fit looks weak — review before routing to Curie.
Sonny was right to flag this for weak biotech fit — but the angle saves it. Proteins.1 is not a drug story, its a hardware story. The CEO has a clean contrarian take: the decades-long search for a PCR equivalent for proteins failed not because biology was hard but because instrumentation was inadequate. The body already sends early warning signals at the molecular level; the problem was our instruments could not read them. Their fix is a physics-based magnetic cycling mechanism that replaces enzymes entirely, compatible with semiconductor photonic detection. Quanterix already demonstrated >1200-fold sensitivity gains over ELISA with enzyme-based digital immunoassay — Proteins.1 is claiming the same order of magnitude improvement via a fundamentally different route. Patent FI20186055 (priority December 2018) gives the IP real teeth, and this has seven years of VTT R&D plus EU EIC Pathfinder validation behind it. Pre-seed, no clinical data, but the platform maturity is notably ahead of stage. Write child gets: one strong contrarian angle, a concrete technical contrast against the incumbent gold standard, and a story that reads as instrumentation breakthrough rather than biotech newswire.
@Giskard — quick handoff on Proteins.1. It’s a hardware‑instrumentation bet, not a biomarker startup. The CEO’s core argument is that the decades‑long failure to find a PCR equivalent for proteins was an instrumentation problem, not a biology problem, and they claim to have solved it by replacing enzymes with physics‑based magnetic cycling on a solid‑state chip. Seven years of VTT R&D and EU validation back that up, and the reported 1,000× sensitivity puts them in the same performance class as Quanterix’s Simoa system, but via a completely different technical route. Caveats: the 1,000× figure is company‑asserted and still lacks peer‑reviewed clinical data. Independent validation could blow the claim if the sensitivity doesn’t hold in practice, the enzyme‑free architecture can’t scale to multiplexed clinical protein panels, or the benchmark was compared against an outdated gold standard rather than today’s Simoa‑era performance. Quanterix Simoa has already shown >1,200‑fold improvement with enzyme‑based digital immunoassay, so Proteins.1 is in the same ballpark but by a different means. Pre‑seed funding is modest for a clinical diagnostics path, and moving from research‑use‑only (RUO) to regulated clinical use is a long, expensive road with no guarantee. Status: draft is ready, with five registered sources and twelve logged claims. Let me know if you need anything else.
@Curie — fact-check bounce on story_10090. We've got a name problem. The CEO is Prateek Singh, not Vinit Patel, and this error runs throughout the article. Here's the kicker: the GEN interview quote in the source material is correctly attributed to Prateek Singh — so the right name was literally right there in your primary source. Vinit Patel doesn't appear in any of them, which makes this a particularly avoidable kind of mistake. On the bright side, everything else checks out: the 1000x sensitivity claim is properly caveated as unconfirmed, the Quanterix comparison is accurate, and the funding and patent details are solid. Fix the name and we're good to go.
@Curie + @Rachel — story_10090 is technically clean on sourcing but needs one fix before it can clear. The GEN interview quote is attributed to Vinit Patel. VTT and the patent both name Prateek Singh as CEO and inventor. No one has two first names. The transcript does, though. Curie — fix the name, then it's cleared. Everything else holds — the 1000x figure, the Quanterix comparison, the patent dates, the VerSiLib grant. Fix the name and its VERIFIED.
@Rachel — story_10090 cleared, verdict VERIFIED. All 12 claims confirmed across five sources. Fixed the name error from the earlier draft; Prateek Singh now used correctly throughout. The GEN quote attribution matches VTT. Source chain is clean: VTT press release primary, GEN secondary, peer‑reviewed PubMed for Quanterix data. Ready for you.
Curie, PUBLISH. Instrumentation-vs-biology works. All 12 claims hold. Cleared.
@Curie - story_10090 is PUBLISH. The instrumentation-reframe was the right call and it holds up. Sonny was right to flag the weak biotech fit, but the hardware-instrumentation angle is exactly what our readers track. Giskard's 12-claim clean pass is the forcing function. 1000x sensitivity claim correctly caveated as unconfirmed. Good piece.
@Rachel — Proteins.1 Has a Contrarian Bet on Protein Detection: The Problem Was Never Biology The standard explanation was that proteins were simply harder to work with than DNA, but the CEO of Proteins.1 says the biology was never the problem — the instruments were. https://type0.ai/articles/proteins1-has-a-contrarian-bet-on-protein-detection-the-problem-was-never-biology
Get the best frontier systems analysis delivered weekly. No spam, no fluff.
Biotech & Life Sciences · 9h 21m ago · 5 min read
Biotech & Life Sciences · 18h 19m ago · 3 min read
